Alamar Biosciences Launches First eMTBR-Tau Immunoassay for Alzheimer's Detection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: Newsfilter
- Innovative Immunoassay: Alamar Biosciences has launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplex panel, which can be immediately deployed on the ARGO™ HT instruments, thereby enhancing early detection capabilities for Alzheimer's disease.
- Significance of Biomarker: eMTBR-Tau serves as a plasma biomarker that specifically reflects tau tangle pathology and has strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring, which is expected to drive advancements in precision medicine.
- Clinical Research Potential: The assay's high sensitivity and specificity provide significant value in clinical research and trials, allowing for direct measurement of biological responses to tau-targeted therapies, addressing the critical need for blood-based biomarkers of treatment efficacy.
- Conference Presentation: Alamar will showcase eMTBR-Tau data at the 2026 Alzheimer’s Association International Conference in London, where researchers will present the assay's analytical performance and its correlation with tau PET imaging, further advancing Alzheimer's research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMR
Wall Street analysts forecast ALMR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 25.660
Low
Averages
High
Current: 25.660
Low
Averages
High
About ALMR
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alamar Biosciences Launches First eMTBR-Tau Immunoassay for Alzheimer's Detection
- Innovative Immunoassay: Alamar Biosciences has launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplex panel, which can be immediately deployed on the ARGO™ HT instruments, thereby enhancing early detection capabilities for Alzheimer's disease.
- Significance of Biomarker: eMTBR-Tau serves as a plasma biomarker that specifically reflects tau tangle pathology and has strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring, which is expected to drive advancements in precision medicine.
- Clinical Research Potential: The assay's high sensitivity and specificity provide significant value in clinical research and trials, allowing for direct measurement of biological responses to tau-targeted therapies, addressing the critical need for blood-based biomarkers of treatment efficacy.
- Conference Presentation: Alamar will showcase eMTBR-Tau data at the 2026 Alzheimer’s Association International Conference in London, where researchers will present the assay's analytical performance and its correlation with tau PET imaging, further advancing Alzheimer's research.
See More
Cathie Wood's Recent Investment Activities Analyzed
- SpaceX Investment Opportunity: Cathie Wood's recent purchase of SpaceX shares marks her first buy since the IPO, despite a 33% pullback in just six days, with the stock still boasting a market cap over $2 trillion, indicating its potential in the future space communications market.
- Roblox User Growth: Although Roblox's stock fell 8%, its daily active users increased by 35% year-over-year to 132 million, suggesting that user engagement is still rising, despite profitability pressures and sequential declines in user numbers.
- Alamar Biosciences Financial Performance: Alamar has generated nearly $26 million in revenue within two months post-IPO, showcasing the potential of its business model, although profitability remains a few years away, its protein detection technology offers significant early disease detection opportunities.
- Investment Strategy Adjustment: Cathie Wood's recent investment strategy reflects a cautious approach towards high-growth tech stocks, with more selling than buying lately, indicating concerns over valuations and future profitability of these companies.
See More
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
Alamar Biosciences Launches First eMTBR-Tau Immunoassay for Alzheimer's Detection
- Innovative Immunoassay: Alamar Biosciences has launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplex panel, which can be immediately deployed on the ARGO™ HT instruments, thereby enhancing early detection capabilities for Alzheimer's disease.
- Significance of Biomarker: eMTBR-Tau serves as a plasma biomarker that specifically reflects tau tangle pathology and has strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring, which is expected to drive advancements in precision medicine.
- Clinical Research Potential: The assay's high sensitivity and specificity provide significant value in clinical research and trials, allowing for direct measurement of biological responses to tau-targeted therapies, addressing the critical need for blood-based biomarkers of treatment efficacy.
- Conference Presentation: Alamar will showcase eMTBR-Tau data at the 2026 Alzheimer’s Association International Conference in London, where researchers will present the assay's analytical performance and its correlation with tau PET imaging, further advancing Alzheimer's research.
See More
Cathie Wood's Recent Investment Activities Analyzed
- SpaceX Investment Opportunity: Cathie Wood's recent purchase of SpaceX shares marks her first buy since the IPO, despite a 33% pullback in just six days, with the stock still boasting a market cap over $2 trillion, indicating its potential in the future space communications market.
- Roblox User Growth: Although Roblox's stock fell 8%, its daily active users increased by 35% year-over-year to 132 million, suggesting that user engagement is still rising, despite profitability pressures and sequential declines in user numbers.
- Alamar Biosciences Financial Performance: Alamar has generated nearly $26 million in revenue within two months post-IPO, showcasing the potential of its business model, although profitability remains a few years away, its protein detection technology offers significant early disease detection opportunities.
- Investment Strategy Adjustment: Cathie Wood's recent investment strategy reflects a cautious approach towards high-growth tech stocks, with more selling than buying lately, indicating concerns over valuations and future profitability of these companies.
See More
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
